Outcomes of multidisciplinary team interventions in the management of sickle cell disease patients with opioid use disorders

References

1. ↵
   1. Jastaniah W

   (2011) Epidemiology of sickle cell disease in Saudi Arabia. Ann Saudi Med 31:289–293.

   OpenUrlCrossRefPubMed
2. ↵
   1. Lanzkron S,
   2. Carroll CP,
   3. Haywood C Jr.

   (2010) The burden of emergency department use for sickle-cell disease:an analysis of the national emergency department sample database. Am J Hematol 85:797–799.

   OpenUrlCrossRefPubMed
3. ↵
   1. Han J,
   2. Zhou J,
   3. Saraf SL,
   4. Gordeuk VR,
   5. Calip GS

   (2018) Characterization of opioid use in sickle cell disease. Pharmacoepidemiol Drug Saf 27:479–486.

   OpenUrl
4. ↵
   1. Levy N,
   2. Sturgess J,
   3. Mills P

   (2018) “Pain as the fifth vital sign”and dependence on the “numerical pain scale”is being abandoned in the US:Why? Br J Anaesth 120:435–438.

   OpenUrlPubMed
5. ↵
   1. Ballas SK

   (2009) The cost of health care for patients with sickle cell disease. Am J Hematol 84:320–322.

   OpenUrlCrossRefPubMed
6. ↵
   1. World Health Organization. Saudi Arabia

   Estimates of Unit Costs for Patient Services fro Saudi Arabia, Updated 2020, Available im URL: https://www.who.int/choice/country/sau/cost/en/. Accessed 2020 January 26.
7. ↵
   1. Ballas SK,
   2. Gupta K,
   3. Adams-Graves P

   (2012) Sickle cell pain:a critical reappraisal. Blood 120:3647–3656.

   OpenUrlAbstract/FREE Full Text
8. ↵
   1. Carroll CP,
   2. Haywood C Jr.,
   3. Fagan P,
   4. Lanzkron S

   (2009) The course and correlates of high hospital utilization in sickle cell disease:Evidence from a large, urban Medicaid managed care organization. Am J Hematol 84:666–670.

   OpenUrlCrossRefPubMed
9. ↵
   1. Embury SH

   1. Shapiro BS,
   2. Ballas SK

   (1994) in Sickle Cell Disease:Basic Principles and Clinical, The acute painful episode, ed Embury SH (Practice Raven Press, New York (NY)), pp 531–543.
10. ↵
    1. Martin JJ,
    2. Moore GP

    (1997) Pearls, pitfalls, and updates for pain management. Emerg Med Clin North Am 15:399–415.

    OpenUrlPubMed
11. ↵
    1. Ahmed SG,
    2. Ibrahim UA

    (2001) Prevalence of therapeutic opiate dependence among patients with sickle cell disease in Maiduguri, Nigeria. Nig J Pharm 32:56–59.

    OpenUrl
12. ↵
    1. Mabayoje VO,
    2. Adeyemo MA,
    3. Akinola NO

    (2015) Case review:Drug addiction in sickle cell disease, a possible ongoing challenge in management of pain. J Glob Biosci 4:2021–2025.

    OpenUrl
13. ↵
    1. Jonassaint CR,
    2. Jones VL,
    3. Leong S,
    4. Frierson GM

    (2016) A systematic review of the association between depression and health care utilization in children and adults with sickle cell disease. Br J Haematol 174:136–147.

    OpenUrlCrossRefPubMed
14. ↵
    1. American Psychiatric Association

    (2013) Diagnostic and Statistical Manual of Mental Disorders:DSM-5 (American Psychiatric association, Washington (DC)), 5th ed, pp 5–25.
15. ↵
    1. Koch KL,
    2. Karafin MS,
    3. Simpson P,
    4. Field JJ

    (2015) Intensive management of high-utilizing adults with sickle cell disease lowers admissions. Am J Hematol 90:215–219.

    OpenUrl
16. ↵
    1. Benjamin LJ,
    2. Swinson GI,
    3. Nagel RL

    (2000) Sickle cell anemia day hospital:an approach for the management of uncomplicated painful crises. Blood 95:1130–1136.

    OpenUrlAbstract/FREE Full Text
17. 1. Wright J,
    2. Bareford D,
    3. Wright C,
    4. Augustine G,
    5. Olley K,
    6. Musamadi L,
    7. et al.

    (2004) Day case management of sickle pain:3 years experience in a UK sickle cell unit. Br J Haematol 126:878–880.

    OpenUrlCrossRefPubMedWeb of Science
18. ↵
    1. Vichinsky EP

    (1991) Comprehensive care in sickle cell disease:its impact on morbidity and mortality. Semin Hematol 28:220–226.

    OpenUrlPubMedWeb of Science
19. ↵
    1. Shapiro BS,
    2. Benjamin LJ,
    3. Payne R,
    4. Heidrich G

    (1997) Sickle cell-related pain:perceptions of medical practitioners. J Pain Symptom Manage 14:168–174.

    OpenUrlCrossRefPubMedWeb of Science
20. ↵
    1. Pack-Mabien A,
    2. Labbe E,
    3. Herbert D,
    4. Haynes J Jr.

    (2001) Nurses'attitudes and practices in sickle cell pain management. Appl Nurs Res 14:187–192.

    OpenUrlCrossRefPubMedWeb of Science
21. ↵
    1. Haywood C Jr.,
    2. Lanzkron S,
    3. Hughes MT,
    4. Brown R,
    5. Massa M,
    6. Ratanawongsa N,
    7. et al.

    (2011) A video-intervention to improve clinician attitudes toward patients with sickle cell disease:the results of a randomized experiment. J Gen Intern Med 62:518–523.

    OpenUrl
22. ↵
    1. Mandell BF

    (2016) The fifth vital sign:A complex story of politics and patient care. Cleve Clin J Med 83:400–401.

    OpenUrlFREE Full Text
23. ↵
    1. Chou R,
    2. Gordon DB,
    3. de Leon-Casasola OA,
    4. Rosenberg JM,
    5. Bickler S,
    6. Brennan T,
    7. et al.

    (2016) Management of postoperative pain:A clinical practice guideline from the American pain society, the American society of regional anesthesia and pain medicine, and the American society of anesthesiologists'committee on regional anesthesia, executive committee, and administrative council. J Pain 17:131–157.

    OpenUrlCrossRefPubMed
24. ↵
    1. Schug SA,
    2. Palmer GM,
    3. Scott DA,
    4. Halliwell R,
    5. Trinca J

    (2015) Acute Pain Management:Scientific Evidence (Australian and New Zealand College of Anaesthetists, Melbourn (VIC)), 4th ed, pp 315–317.
25. ↵
    1. Scott DA,
    2. Mc DONALD WM

    Clinical Pain Management, Assessment, Measurement and History. Macintyre PE, Walker SM, Rowbotham DJ, editors (Hodder &Stoughton Limited, Acute Pain. London (NW)), 2nd ed, pp 135–150.
26. ↵
    1. Sinha CB,
    2. Bakshi N,
    3. Ross D,
    4. Krishnamurti L

    (2019) Management of chronic pain in adults living with sickle cell disease in the era of the opioid epidemic:A qualitative study. JAMA Netw Open 2:e194410.

    OpenUrl
27. ↵
    1. Artz N,
    2. Whelan C,
    3. Feehan S

    (2010) Caring for the adult with sickle cell disease:results of a multidisciplinary pilot program. J Natl Med Assoc 102:1009–1016.

    OpenUrlPubMed